IL2 and head and neck cancer: al. analyzed 19 previously described proteins in head and neck cancer patients before treatment, and they found that there was a significant difference between the baseline levels of the patient and the control group in IL-2, IL-4, EGFR, OPN, VEGFR-1, VEGFR-2, VEGF and GRO levels, but none of these markers could be correlated with outcome [31].